Designed By Experts: BOOST® Advanced Nutritional Shake Supports the Nutritional Needs of Adults on a GLP-1 Weight Loss Journey
New Ready-to-Drink Shake Features Key Nutrients to Support Lean Muscle, Digestive Health and Help Promote Energy Metabolism
BRIDGEWATER, N.J., June 2, 2025 /PRNewswire/ -- The BOOST® Nutritional Drink brand unveiled today its new BOOST® Advanced Nutritional Shake designed to support nutritional needs during a weight management journey for adults who are on GLP-1s^, dieting or exercising. Each serving provides 35g of high-quality protein to support muscle health*, 4g of prebiotic fiber for digestive health and 8 essential B-vitamins to support energy metabolism. These nutritional shakes can be added to the diet to increase protein during weight loss and should be incorporated into a nutritionally balanced diet with exercise.† BOOST® Advanced Nutritional Shakes are available in Rich Chocolate and Very Vanilla flavors and are found nationwide at ShopRite, Meyer and on Amazon.com and BOOST.com.
'We recognize weight management is a personal journey, and it can be overwhelming for adults to implement numerous changes into their diet and lifestyle at once,' said Krysmaru Araujo-Torres, M.D., Head of Medical Affairs, the BOOST® brand. 'That's why we formulated the new BOOST Advanced Nutritional Shake with key nutrients in a ready-to-drink package to make it easy for adults to achieve and sustain their individual nutrition and wellness goals. For instance, protein is important in maintaining lean muscle for physical function and for the body's ability to maintain weight loss. And, the adult population generally doesn't meet daily requirements for fiber, so adding 4g of fiber to the BOOST Advanced shake helps consumers achieve their fiber intake goals alongside other key nutrients.'
BOOST Advanced Nutritional Shakes feature key macro- and micro-nutrients to support nutritional needs during weight loss, including:
The BOOST Advanced Nutritional Shake provides the highest amount of protein per serving within the BOOST® brand of products. It is specifically formulated to support nutrition during weight loss and provides 4g of prebiotic fiber to support digestive health and a healthy gut microbiome, which are particularly important for people experiencing reduced appetite or on weight management journeys.
BOOST Advanced Nutritional Shakes join the brand's other nutritional beverages, including BOOST® Pre-Meal Hunger Support Nutritional Drink. Designed for adults to consume 10-30 minutes prior to a meal, BOOST Pre-Meal Hunger Support Nutritional Drink helps manage hunger and feel satisfied, and promotes the body's natural production of the hormone GLP-1 in response to a meal.** Each ready-to-drink serving provides 10g of clinically studied whey protein, 45 calories and 1g sugars. It's available in a light tasting Mocha flavor.
To learn more about BOOST products, please visit www.BOOST.com.
About BOOST®
BOOST® is a leading nutritional supplement beverage brand that helps provide balanced nutrition, including protein, calories, and essential vitamins and minerals. For active adults looking to up their protein intake and help fuel their exciting next chapter, BOOST® nutritional drinks are a convenient, nutrient-packed snack or mini meal to help individuals reach their nutrition goals. Available in 10 different flavors and 12 different varieties, including BOOST® High Protein, BOOST® Original, BOOST Plus®, BOOST® MAX, BOOST Glucose Control® and BOOST® Advanced nutritional drinks, there's a BOOST® product that offers unique nutritional support, so you can live your best life in the here and now. Learn more at www.BOOST.com.
*When incorporated into a weight management plan that includes diet and exercise.
**Incorporate BOOST Pre-Meal Hunger Support Nutritional Drink into a balanced diet as part of a medically supervised weight management plan.
†Use BOOST® Advanced Nutritional Shakes as a food supplement only. Do not use for weight reduction.
^This product should not be used to substitute for medication and does not make medication, including GLP-1 medication, more effective.
Media Contact
Andrea Martin
BOOST® brand
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/designed-by-experts-boost-advanced-nutritional-shake-supports-the-nutritional-needs-of-adults-on-a-glp-1-weight-loss-journey-302470233.html
SOURCE BOOST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Hong Kong Airlines Celebrates Inaugural Flight to Sydney
Offering Travellers More Direct Flight Options to Australia HONG KONG, June 21, 2025 /PRNewswire/ -- Hong Kong Airlines' inaugural flight between Hong Kong and Sydney, Australia, departed yesterday, making it the second local airline to operate this route and providing greater travel options for business, leisure, and transit passengers. To mark this new milestone in its network expansion, Hong Kong Airlines held celebratory events at both Hong Kong International Airport (HKIA) and Sydney Airport (SYD). Prior to departure, a launch ceremony was held at the boarding gate of the HKIA. The event was attended by distinguished guests, including Mr Jeff Sun, President of Hong Kong Airlines; Mr Ian McGraw from the Australian Consulate-General in Hong Kong; Ms Carmen Tam and Ms Vivien Yuen from Tourism Australia; Ms Jennifer Tung from Destination New South Wales; and Mr Ricky Chong from Airport Authority Hong Kong. The guests interacted with passengers and presented them with bespoke souvenirs to commemorate the historic occasion. During the event, Hong Kong Airlines President Mr Jeff Sun stated: "As a full-service local carrier, the launch of our Sydney service marks a significant step in our transformation to an international airline. Sydney is not only a popular destination for leisure and business travel but also one of Australia's most vital economic hubs. The expansion of the bilateral traffic rights agreement allows us to offer more choice to travellers in both cities, strengthening the connection between them." He added, "While Hong Kong Airlines may be a younger brand in the mature Australian market, we are endeavouring in our commitment to providing quality service. We operate this route with our Airbus A330 aircraft, featuring comfortable business and economy class cabins, and strive to deliver a passenger-centric in-flight experience through attentive service and fine dining for our long-haul customers." Sydney Airport CEO Mr Scott Charlton said: "We're proud to welcome Hong Kong Airlines to Sydney as our 52nd airline partner with its strong reputation for service excellence, efficiency and value. This inaugural service comes on the back of the first expansion in bilateral air traffic rights between Australia and Hong Kong in 19 years and we thank the Albanese Federal Government for its role in enabling this important agreement, which reflects the strength of our longstanding cultural and economic ties." NSW Minister for Jobs and Tourism Steve Kamper, said: "Hong Kong is a priority international market for NSW, with incoming travellers contributing substantially to the NSW visitor economy. The Minns Labor Government has made it very clear; we want to grow our visitor economy and the best way to do this is by increasing airline capacity and unlocking new international markets for NSW. We've set our sights on increasing the state's aviation capacity by 8.5 million seats, and this new Hong Kong route will complement other new routes we're securing as we work towards landing this goal." Mr Wang Yu, Consul General of People's Republic of China (Sydney), said: "As the second Hong Kong-based airline to operate the Hong Kong–Sydney route, Hong Kong Airlines not only provides a convenient new option for traveling between China and Australia, but also contributes to enhanced exchanges among students, tourists, business professionals and friends from all walks of life. This new service will strengthen Hong Kong and Sydney's role as vital gateways for the flow of people and goods, injecting fresh momentum into the economic and cultural ties between China and Australia. Its launch will also attract more international travelers to transit through Hong Kong or Sydney, further strengthening both cities' positions as global aviation hubs and creating new opportunities for trade and investment. Looking ahead, the Consulate-General of China in Sydney will continue to encourage and support airlines from both China and Australia in restoring or launching new routes based on the principle of mutual benefit and win-win cooperation. We believe that Hong Kong Airlines will continuously enhance its service quality and showcase a good corporate image." Also in attendance at the Sydney welcome ceremony were representatives from the Consulate-General of the People's Republic of China in Sydney, Destination NSW and the Hong Kong Economic and Trade Office (Sydney). Exclusive Lounge Access for Connecting Passengers To celebrate the launch of the new service, passengers travelling on this route and transit at Hong Kong for selected Hong Kong Airlines flights* to Vancouver, Bali, Tokyo, Osaka, Fukuoka, Shanghai (Pudong), Haikou, or Sanya, between 20 June and 31 October 2025, will receive complimentary access to the airline's flagship lounge "Club Autus" at Hong Kong International Airport. *Please click here for the relevant terms and conditions. Expanding Route Network The launch of the Sydney service indicates Hong Kong Airlines' overarching strategy for its network expansion. Coupled with the various significant destinations that have been inaugurated or reinstated since the start of the year, including Gold Coast in Australia, Vancouver in Canada, and Hulunbuir in Inner Mongolia of mainland China, the airline has cultivated a more extensive and diversified route map. This further underscores Hong Kong Airlines' commitment and contribution to the aviation industry's recovery and long-term development. In addition to the new routes, the Company also increased the frequency of services on multiple routes to cater to the summer travel demand. This includes the resumption of seasonal flights to the Maldives and an increase in flights to Da Nang to two per day. Additionally, flights to Shanghai Pudong will be increased to four per day, while services to Hangzhou and Nanjing will become twice day. The variety of flight times available throughout the day provides business, leisure, and transit passengers with the flexibility to plan their itineraries. The Company will launch another new service in July, providing passengers with more travel options. Hong Kong Airlines flight schedule* between Hong Kong and Sydney is as follows (All times local): Route Flight Number Departure Arrival Frequency HKG – SYD HX017 22:25 09:50+1 Daily SYD – HKG HX018 11:30 19:10 * Flight number and schedule may change without prior notice Please download high-resolution photos through this link. About Hong Kong Airlines Established in 2006, Hong Kong Airlines is a full-service airline firmly rooted in Hong Kong. The airline flies to over 30 destinations across the Asia Pacific and North America, and currently maintains interline and codeshares with multiple airline partners and ferry service providers. Hong Kong Airlines operates an all-Airbus fleet. It has been awarded the internationally acclaimed four-star rating from Skytrax since 2011. For more information, please visit or our social media channels on LinkedIn, Twitter, Instagram and Facebook. View original content to download multimedia: SOURCE Hong Kong Airlines Inicia sesión para acceder a tu portafolio
Business Upturn
20 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
a day ago
- Yahoo
China's Tai'an Mining Equipment Accelerates 'Going Global'
TAI'AN, China, June 20, 2025 /PRNewswire/ -- This is a report from the Shandong 0ffice of Hong Kong Business Daily. Recently, the "Vietnam China Shandong (Tai'an) Mining and Processing Technology Exhibition" was held in Vietnam to assist mining equipment enterprises in Tai'an City in exploring the Southeast Asian market. This exhibition is the first overseas self held exhibition of Tai'an's "Mount Taishan Brand Global Travel" campaign. A total of 21 mining equipment enterprises went to Vietnam to participate in this event, achieving an intended turnover of more than 50 million dollars, reaching more than 50 agency cooperation intentions, and achieving good trade results. This exhibition adopts a three in one model of "exhibition+trade docking+promotion", which provides a new platform for Sino Vietnamese mining equipment industry cooperation for enterprises. During the event, 126 buyers including Vietnam Coal Group were attracted to negotiate and connect. Tai'an Chuangdong New Material Technology Co., Ltd. signed a 1.2 million head order at the exhibition site, with an annual procurement scale of over 10 million US dollars, and simultaneously reached a memorandum of cooperation on new product technology. Shandong Ruiyu Mining Materials Processing Co., Ltd. seized the opportunity of cooperation in the raw material supply chain, opened up new growth points for subsequent business, successfully entered the largest support material supply chain system in Vietnam, and is expected to export over 2000 tons of goods annually. Tai'an Mount Taishan Huakun Machinery Co., Ltd. signed a technical cooperation memorandum with Yuemei Group on intelligent upgrading; Yongtai Mining Technology Co., Ltd. in Daiyue District, Tai'an City has obtained 5 customer process improvement needs, and 2 Vietnamese buyers plan to visit Thailand in June to inspect production lines and carry out deeper cooperation. The Tai'an Municipal Bureau of Commerce held a meeting to discuss the supply and demand of mining and processing technology equipment in Vietnam (Tai'an), and visited leading units in the Vietnamese coal mining industry such as the Vietnam Coal Mining Industry Group and the Vietnam Machinery Association. Next, Tai'an will continue to implement the activity of "Mount Taishan Brand Global Travel", organize and carry out key exhibitions such as "Russian International Construction and Construction Machinery Exhibition", "Sri Lanka Colombo Building Materials and Construction Machinery Exhibition", "Oman Construction Machinery and International Building Materials Exhibition", and help foreign trade enterprises in Tai'an expand emerging markets in Central Asia, the Middle East, Africa, etc. View original content: SOURCE Shandong Office of Hong Kong Business Daily
